News on protein analysis, clinical proteomics, biomarkers in genetics, genomics, and molecular diagnostics.
While proteogenomic technology is still in its early stages, it will likely make its way into the clinic over the next five to 10 years, said an FDA official.
The test, which measures the kinetics of amyloid beta isoforms in blood, could enable more efficient screening of patients for Alzheimer's drug trials.
The agencies said they're aiming to "accelerate the development of proteogenomic technologies and biomarkers, as it relates to precision medicine in cancer."
While actual clinical implementation remains distant, MALDI imaging technology has advanced to the point where it might feasibly be applied to pathology.
The company expects the deal will help it launch an immunostaining technology, expand into US pharma services, and establish itself as a genetic testing leader in Japan.
Helix customers can purchase apps that interpret different aspects of their genome, Technology Review reports.
The New York Times reports that a number of companies and research institutes are pursuing gene therapies.
Salmon with shorter telomeres survive to make the trip back to their river homes, New Scientist reports.
In PLOS this week: vaginal microbiome composition, population patterns of Chagas-carrying Rhodnius ecuadoriensis, and more.